Compare Credo Technology Group Holding Ltd (CRDO) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Credo Technology Group Holding Ltd trades at $213.41 (market cap $39.82B), while Recursion Pharmaceuticals Inc trades at $3.96 (market cap $2.14B). The key difference: Credo Technology Group Holding Ltd is far larger — about 18.6× Recursion Pharmaceuticals Inc's market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| CRDO | RXRX | |
|---|---|---|
Market Cap | $39.82B | $2.14B |
Volume | 9,451,558 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $302.52 | $6.79 |
52-Week Low | $87.81 | $2.84 |
Typical Hold Time | 22 Days | 22 Days |
Enterprise Value | $39.08B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $220.01, down 0.37% on the day, with strong technical momentum showing bullish moving averages and key support at $213. The company demonstrates exceptional fundamental strength with 114.7% YoY revenue growth and 33.83% net income margins, though valuation metrics remain elevated with a P/E of 74.6. Recent earnings beats and analyst optimism highlight CRDO's position in AI infrastructure connectivity.
Outlook remains positive given triple-digit revenue growth and expanding AI data center demand, but premium valuation and insider selling present near-term risks. Wall Street consensus targets $267.33 with 87.5% buy ratings, though execution risks and customer concentration require monitoring amid rapid expansion.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
